Your browser doesn't support javascript.
Platelet reactivity testing in peripheral artery disease.
Zhang, Youqi; Chou, Jennifer W; Huang, Wan-Ting; Derry, Katrina; Humber, Doug.
  • Zhang Y; Department of Pharmacy, Oregon Health & Science University, Portland, OR, USA.
  • Chou JW; Department of Pharmacy, UC San Diego Health, La Jolla, CA, USA.
  • Huang WT; Department of Pharmacy, UC San Diego Health, La Jolla, CA, USA.
  • Derry K; Department of Pharmacy, UC San Diego Health, La Jolla, CA, USA.
  • Humber D; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA.
Am J Health Syst Pharm ; 79(16): 1312-1322, 2022 08 05.
Article in English | MEDLINE | ID: covidwho-1774339
ABSTRACT

PURPOSE:

Oral antiplatelet therapy is routinely used to prevent adverse cardiovascular events in patients with peripheral artery disease (PAD). Several laboratory tests are available to quantify the degree of platelet inhibition following antiplatelet therapy. This article aims to provide a review of the literature surrounding platelet functional testing in patients with PAD receiving oral P2Y12 inhibitors and to offer guidance to clinicians for the use and interpretation of these tests.

SUMMARY:

A literature search of PubMed and the Web of Science Core Collection database was conducted. All studies that performed platelet function testing and reported clinical outcomes in patients with PAD were included. Evaluation of the data suggests that, among the available testing strategies, the VerifyNow platelet reactivity unit (PRU) test is the most widely used. Despite numerous investigations attempting to define a laboratory threshold indicating suboptimal response to antiplatelet therapy, controversy exists about which PRU value best correlates with cardiovascular outcomes (ie, mortality, stent thrombosis, etc). In the PAD literature, the most commonly used PRU thresholds are 208 or higher and 235 or higher. Nonetheless, adjusting antiplatelet regimens based on suboptimal P2Y12 reactivity values has yet to be proven useful in reducing the incidence of adverse cardiovascular outcomes. This review examines platelet function testing in patients with PAD and discusses the interpretation and application of these tests when monitoring the safety and efficacy of P2Y12 inhibitors.

CONCLUSION:

Although platelet functional tests may be simple to use, clinical trials thus far have failed to show benefit from therapy adjustments based on test results. Clinicians should be cautioned against relying on this test result alone and should instead consider a combination of laboratory, clinical, and patient-specific factors when adjusting P2Y12 inhibitor therapy in clinical practice.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Platelet Aggregation Inhibitors / Peripheral Arterial Disease Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Reviews Limits: Humans Language: English Journal: Am J Health Syst Pharm Journal subject: Pharmacy / Hospitals Year: 2022 Document Type: Article Affiliation country: Ajhp

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Platelet Aggregation Inhibitors / Peripheral Arterial Disease Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Reviews Limits: Humans Language: English Journal: Am J Health Syst Pharm Journal subject: Pharmacy / Hospitals Year: 2022 Document Type: Article Affiliation country: Ajhp